河北医学2012，Vol.18Issue(6)：787-789,3.DOI:10.3969/j.issn.1006-6233.2012.06.030
依达拉奉联合丁苯酞对进展性卒中治疗的临床研究
Clinical Observation of Edaravone Combination of Butylphthalide in Treatment of Advancing Stroke
林晓光1
作者信息
- 1. 南京大学附属南京鼓楼医院集团宿迁市人民医院神经内科,江苏,宿迁,223800
- 折叠
摘要
Abstract
Objective: To evaluate the effect of combination of butylphthalide in the treatment of the a-cute advancing stroke. Method: The incidence of advancing stroke in 72h patients with 120 patients, randomly divided into 60 patients with treatment group and control group with 60 patients. The control group with conventional therapy, namely in the given improve microcirculation, and intracranial pressure regulating blood pressure and blood glucose and other symptomatic treatment given based on SBR peptide 0. 2g, daily 3, course of treatment is 14 days; the treatment group on the basis of routine treatment of edaravone 30mg joined 100mL saline infusion, 2 times daily, with 14 days, Butylphthalide 0. 2g for 3 times a day, 14 days in a course. Two cases of the United States of America NIH Stroke Scale ( NIHSS ) score and ability of daily living ( BI ) score. Result: Treatment group and control group in the NIHSS score and BI score in the 14 days after treatment, 1 month are statistical differences ( P < 0. 05 ). Conclusion:The application effect of edaravone combined butylphthalide is better than that of butylphthalide treating progressing stroke.关键词
进展性卒中/依达拉奉/丁苯酞Key words
Advancing stroke/Edaravone/Butylphthalide引用本文复制引用
林晓光..依达拉奉联合丁苯酞对进展性卒中治疗的临床研究[J].河北医学,2012,18(6):787-789,3.
